THE DEAL, AT A GLANCE
From the announcementEpicrispr
01What it doesWith EPI-321, Epicrispr is using this strategy to silence the genetic driver of facioscapulohumeral muscular dystrophy, or FSHD, a progressive neuromuscular condition.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedEpicrispr raised $90M, announced 2026-08-11From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersEpicrispr's $90M financing represents an above-median capital allocation within a crowded FinTech funding tape, signaling that large private rounds are still clearing…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Epicrispr · Financing Record
Explore source-linked visual explanations for Epicrispr. Unsupported claims are withheld while source review continues.
Record 10059 · Recorded date: 2026-08-11
Explore company records →